Access to Medicine Versus Test Data Exclusivity: by Owais H. Shaikh

By Owais H. Shaikh

This publication explores the concept that of attempt facts exclusivity safety for prescribed drugs. concentrating on artwork 39(3) of the WTO contract on Trade-Related elements of highbrow estate Rights (TRIPS contract) and correct provisions in chosen unfastened alternate agreements (FTA) and nationwide legislation, it combines normative, ancient, comparative and fiscal research of try out information exclusivity protection.
At the center of this ebook is the radical and unique Index of information Exclusivity and entry (IDEAS), which analyzes the effectiveness of try facts exclusivity provisions in FTAs and nationwide legislation either at the power of exclusivity in addition to on entry to medication. rules presents a framework for the review of present attempt info exclusivity security criteria at the foundation in their proximity to Article 39(3) of the journeys contract, the scope of exclusivity and the flexibilities in FTAs, and for that reason in nationwide laws. 
This publication goals to develop nationwide and overseas coverage makers’ snatch of many of the nuances of try information exclusivity safeguard. in addition, it presents functional strategies in regards to designing a suitable criminal procedure with a robust specialise in selling entry to medication for all.

Show description

Read or Download Access to Medicine Versus Test Data Exclusivity: Safeguarding Flexibilities Under International Law (Munich Studies on Innovation and Competition) PDF

Similar commercial books

Pattern Cutting and Making Up

Significant adjustments have happened within the previous few years within the equipment of slicing and production outerwear. mild garments businesses at the moment are production those heavy clothing a result of improvement of fusible interlinings and new production thoughts that have led to the deskilling of conventional tailoring equipment.

Essays on New Institutional Economics

This choice of essays contains a few of Rudolf Richter’s very important contributions to investigate on New Institutional Economics (NIE). It bargains with the significant thought, rules, and method of recent Institutional Economics and explores its relation to sociology and legislations. different chapters learn purposes of NIE to numerous microeconomic and macroeconomic concerns within the face of uncertainty, from entrepreneurship to the euro situation.

Additional info for Access to Medicine Versus Test Data Exclusivity: Safeguarding Flexibilities Under International Law (Munich Studies on Innovation and Competition)

Example text

See Sect. 2 for a detailed discussion of newness requirement of Art 39(3) TRIPS and also in the context of test data exclusivity. 19 For the grant of five year test data exclusivity protection in the US, there is no requirement of proving that the underlying pharmaceutical product is better than the existing therapies. 108(b)(2) (2003). Similarly, three year exclusivity is available where new clinical studies that are essential to the approval of the application are conducted. There too, a requirement of therapeutic advancement is absent.

59 The study also presented price comparison of a sample of pharmaceutical products with test data exclusivity with non-data protected products made available by the Ministry of Health. pdf +html (last visited 2 June 2016) [hereinafter Shaffer & Brenner (2009)]. 58 Id at w961. ’ Id at w964-5. 60 Id at w963-4 (see Exhibit 3). 61 Miguel E. C. Gamba et al, Impacto de 10 a~ nos de protecci on de datos en medicamentos en Colombia, Serie Buscando Remedio No. pdf (last visited 2 June 2016). 62 According to the English abstract of the report which is only available in Spanish, ‘[t]his figure was calculated from the total spending on protected new chemical entities during the period, compared with “theoretical” spending at competitive prices.

1. Legal exclusivities attempt to restore some of the initial excludability of the public good, enabling private appropriation of the the benefits of its exploitation. 24 2 Test Data Exclusivity: Raison d’eˆtre will be under-produced without appropriate incentives. But is it right to assume that test data would not be produced if not specifically incentivized? Moreover, is it necessary to confer an exclusive right as an incentive to produce such data? 12 In fact in the present case, test data is a public good that is, at best, an intermediate product, necessary for the production of the end product, the pharmaceuticals.

Download PDF sample

Rated 4.10 of 5 – based on 42 votes